PopVax – Socially Bharat

socially bharat
January 14, 2025
4 Mins Read

PopVax is Awarded 2 Million USD as One of the Winners of the BARDA Patch Forward Prize for its Seasonal Influenza Vaccine built on a Novel mRNA-encoded Immunogen Display Architecture Delivered via Dissolvable Microarray Patch

PopVax, an Indian full-stack biotechnology company developing broadly-protective mRNA vaccines using machine learning-enabled computational protein design, is delighted to announce that it has been awarded

88 Views
0 Comments

socially bharat
November 14, 2024
3 Mins Read

PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax’s Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government’s Project NextGen

MUMBAI, India & HYDERABAD, India: PopVax, an Indian full-stack biotechnology company developing novel mRNA vaccines and therapeutics using machine learning-enabled computational

171 Views
0 Comments

socially bharat
October 30, 2024
3 Mins Read

PopVax Announces 1.15 Million USD in Funding from the Bill and Melinda Gates Foundation for Thermostable mRNA Delivery Formulation Development

MUMBAI, India & HYDERABAD, India: PopVax, an Indian full-stack biotechnology company developing novel mRNA vaccines and therapeutics using computational protein design,

134 Views
0 Comments

PopVax is Awarded 2 Million USD as One of the Winners of the BARDA Patch Forward Prize for its Seasonal Influenza Vaccine built on a Novel mRNA-encoded Immunogen Display Architecture Delivered via Dissolvable Microarray Patch

Quick Links

Contact Us

Stay Updated

Share Your Message!